Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
- Conditions
- Interventions
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT01395537
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Use Investigation for TYKERB Tablet (All Case Investigation)
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 4054
- Registration Number
- NCT01332396
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT01328054
- Locations
- 🇺🇸
GSK Investigational Site, Salt Lake City, Utah, United States
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 647
- Registration Number
- NCT01306045
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01300962
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT01290354
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT01273610
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT01264081
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
- Conditions
- Interventions
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2013-01-11
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 3
- Registration Number
- NCT01245660
- Locations
- 🇫🇷
CHU Bordeaux - Hôpital Saint André - Department of Medical Oncology, Bordeaux, France
Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 82
- Registration Number
- NCT01218529
- Locations
- 🇬🇷
University Hospital of Larissa, Dept of Internal Medicine, Oncology Section, Larissa, Greece
🇬🇷Metropolitan Hospital, 1st Dept of Medical Oncology, Athens, Greece
🇬🇷General Hospital of Athens 'Hippokratio', 2nd Dept of Internal Medicine, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.